Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
3.420
-0.130 (-3.66%)
At close: Jan 20, 2026, 4:00 PM EST
3.400
-0.020 (-0.58%)
After-hours: Jan 20, 2026, 7:57 PM EST
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,582,750
Market Cap
190.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | 38 | 15 | 65.22% | 37 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QNCX News
- 8 days ago - Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
- 5 weeks ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 5 weeks ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire
- 2 months ago - Quince Therapeutics to Participate at Investor Events in December 2025 - Business Wire
- 2 months ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting - Business Wire
- 3 months ago - Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript - Seeking Alpha